---
figid: PMC4404310__nihms326998f1
figtitle: Proposed schema of aberrant signal transduction mediated by the TSLPR heterodimer
  in CRLF2-overexpressing ALL
organisms:
- NA
pmcid: PMC4404310
filename: nihms326998f1.jpg
figlink: /pmc/articles/PMC4404310/figure/F1/
number: F1
caption: Proposed schema of aberrant signal transduction mediated by the TSLPR heterodimer
  in CRLF2-overexpressing ALL. JAK/STAT, PI3K, and possibly MAPK signaling networks
  are hyperactive. Targeting hyperactive signaling nodes with STIs (such as JAK, PI3K
  pathway, and MEK inhibitors) is a rational therapeutic strategy for preclinical
  and clinical testing.
papertitle: Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic
  Leukemia.
reftext: Sarah K. Tasian, et al. Crit Rev Oncog. ;16(0):13-24.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9439856
figid_alias: PMC4404310__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4404310__F1
ndex: 98bca221-deb4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4404310__nihms326998f1.html
  '@type': Dataset
  description: Proposed schema of aberrant signal transduction mediated by the TSLPR
    heterodimer in CRLF2-overexpressing ALL. JAK/STAT, PI3K, and possibly MAPK signaling
    networks are hyperactive. Targeting hyperactive signaling nodes with STIs (such
    as JAK, PI3K pathway, and MEK inhibitors) is a rational therapeutic strategy for
    preclinical and clinical testing.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TSLP
  - CRLF2
  - IL7R
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - STAT5A
  - STAT5B
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EIF4EBP1
  - EIF4E
  - EIF4E2
  - EIF4E3
  - EPHB2
  - MAPK1
  - MAPK3
  - Cancer
---
